We are delighted to announce that Dr Timothy Crook, Consultant Medical Oncologist at Cromwell Hospital, is presenting alongside international colleagues at the European Society for Medical Oncology (ESMO) in October. The ESMO is the leading European society for oncological education and information, with more than 30,000 members – oncology experts from 168 countries worldwide. The… Continue reading ESMO 2023 – Dr. Crook presents together with Datar Cancer Genetics
The US Food and Drug Administration (FDA) has now also granted our blood test for the diagnosis of CNS tumours a “Breakthrough Device Designation”. Following our blood tests for the early detection of prostate and breast cancer, this is the third test to receive this designation from the FDA. If tumours are considered inoperable or… Continue reading Further Breakthrough Device Designation from the FDA – now also for blood test to diagnose inaccessible brain tumours
We are pleased to announce that Dr Massimo Cristofanilli, Dr Razelle Kurzrock as well as Prof Sendurai Mani have agreed to join our Scientific Advisory Board. Dr. Massimo Cristofanilli will chair the Scientific Advisory Board in the future. Dr Cristofanilli is an internationally recognised physician, researcher and ambitious scientist. Among other things, he has developed… Continue reading RENOWNED ASSIGNMENT TO THE SCIENTIFIC ADVISORY BOARD OF DATAR CANCER GENETICS
Distinguishing patients with intracranial malignancies from those with benign diseases is difficult, as the symptoms are often non-specific. This study investigates whether the detection of glial malignancies based on the enrichment and identification of circulating glial cells (CGCs) in peripheral blood is an effective strategy for the rapid and simple diagnostic stratification of such patients.… Continue reading PROMISING INITIAL STUDY RESULTS IN THE DETECTION OF GLIAL MALIGNANCIES USING GLIAL CELLS IN THE BLOOD
The case study shows that cancer patients with rare tumour entities can benefit from a broader molecular-genetic tumour profile. This is important for cancer patients for whom empirical therapies are ineffective and potential therapies are being researched based on tumour-specific profiles and taking into account possible resistance mechanisms. The publication was produced in collaboration with… Continue reading HOT NEWS! OUR LATEST PUBLICATION IN FRONTIERS IN MEDICINE
We are pleased to announce that we have recently signed a USD 250 million contract with Artemis DNA. Artemis DNA is a leading US-based diagnostic laboratory company providing proprietary next generation sequencing (NGS) gene tests and diagnostic laboratory services for a variety of medical specialities, including cardiology, oncology, immunology, neurology, reproductive medicine and pharmacogenomics. Under… Continue reading MARKET ENTRY IN THE USA THANKS TO AGREEMENT WITH ARTEMIS DNA
After TrucheckTM Breast, a blood test for the detection of early-stage breast cancer, has already received “Breakthrough Device Designation” from the FDA, this has now also been announced for Trublood Prostate. Both tests are CE-certified and already available in Europe. Trublood Prostate is the first blood test that can detect early-stage prostate cancer with high… Continue reading Screeening test for the early detection of prostate cancer also receives “Breakthrough Device Designation” from the FDA
